Compare AbCellera Biologics Inc (ABCL) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? AbCellera Biologics Inc trades at $10.35 (market cap $2.99B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.87. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | SJNK | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | Sector/Thematic |
52-Week High | $9.76 | $25.63 |
52-Week Low | $2.78 | $24.75 |
Enterprise Value | $2.58B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
SJNK trades at $24.87, up 0.16% over 24 hours, with a bearish technical signal driven by moving averages. The ETF shows neutral oscillators and has announced upcoming dividend payments. Recent news highlights institutional selling, with Cetera Investment Advisers and Balefire LLC reducing positions in Q2 2026.
The outlook remains cautious due to bearish technicals and institutional outflows. Risks include high-yield bond sensitivity to interest rates and economic conditions. Analyst sentiment is negative, with recent articles advising against holding junk bonds amid potential yield headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
